

Review of: "Sotorasib Treatment Could Worsen the Prognosis of Advanced KRASG12C-Mutated Non-Small Cell Lung Cancer"

Massimiliano Spada¹

¹ Fondazione Istituto G. Giglio di Cefalù, Cefalù, Italy

Potential competing interests: No potential competing interests to declare.

I believe it is appropriate to focus on the choice of drug used in the control arm: docetaxel is not the first option in many countries, especially European ones, due to its toxicity. I believe this in-depth analysis can give even more value to the arguments proposed.